Abbott Laboratories vs. Akari Therapeutics plc ADR (0.01 USD)
Abbott Laboratories (ABT) comes out ahead, leading on 4 of 5 compared factors.
Size & Scale
| ABT | AKTX | |
|---|---|---|
| Market Cap | $176.90 billion | $17.83 million |
| Revenue (TTM) | $46.59 billion | — |
| Net Income (TTM) | $5.42 billion | $-30,960,000 |
ABT leads on 2 of 2 size & scale factors.
Valuation
| ABT | AKTX | |
|---|---|---|
| P/E Ratio | 33.28 | — |
| Price / Book | 3.42 | 0.96 |
| Price / Sales | 3.80 | — |
AKTX leads on 1 of 1 valuation factors.
Profitability
| ABT | AKTX | |
|---|---|---|
| Net Margin | 11.65% | — |
| Return on Equity | 10.48% | -166.50% |
ABT leads on 1 of 1 profitability factors.
Dividend
| ABT | AKTX | |
|---|---|---|
| Dividend Yield | 2.45% | — |
| Payout Ratio | 81.55 | — |
ABT and AKTX split the dividend factors evenly.
Risk & Sentiment
| ABT | AKTX | |
|---|---|---|
| Short Interest | 0.57% | 30.21% |
ABT leads on 1 of 1 risk & sentiment factors.
Dig deeper: ABT overview, ABT financials, AKTX overview, AKTX financials.
Comparisons use delayed, cached fundamental data and cover only the factors shown. For informational purposes only — not investment advice.